Navigation Links
Pharmacopeia Acquires Selective Androgen Receptor Modulator ('SARM') Program from Bristol-Myers Squibb
Date:10/15/2007

egrated drug discovery platform to sustain the growth of its development pipeline. Pharmacopeia has established strategic alliances with major pharmaceutical and biotechnology companies, including Bristol-Myers Squibb, Cephalon, GlaxoSmithKline, Organon, Schering-Plough, and Wyeth Pharmaceuticals. For more information please visit the company's website at http://www.pharmacopeia.com.

Contact:

Brian M. Posner

Executive Vice President and Chief

Financial Officer

(609) 452-3643

ir_pr@pcop.com

This press release, and oral statements made with respect to information contained in this press release, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include those which express plan, anticipation, intent, goal, contingency or future development and/or otherwise are not statements of historical fact. These statements are based upon management's current expectations and are subject to risks and uncertainties, known and unknown, which could cause actual results and developments to differ materially from those expressed or implied in such statements. These forward- looking statements include, but are not limited to, statements about the successful implementation of Pharmacopeia's strategic plans, Pharmacopeia's plans to develop PS178990, a product candidate from its SARM program, Pharmacopeia's plans to develop PS433540, a product candidate from its DARA program, Pharmacopeia's Phase 1 clinical studies with respect to PS178990, Pharmacopeia's Phase 1 and Phase 2 clinical studies with respect to PS433540, including timing and expected outcomes of such studies, Pharmacopeia's estimates of the market opportunities for its product candidates, including PS178990 and PS433540, Pharmacopeia's ability to successfully perform under its collaborations with Brist
'/>"/>

SOURCE Pharmacopeia
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. Ossur Acquires the U.S. Orthopaedics Company
2. Stem of Hope: Stem Cell Research Acquires a Brittle Star As A model
3. Pfizer Acquires Worldwide Rights For New Overactive Bladder Drug
4. Premier Army Hospital Acquires PET-CT Scanner
5. Wockhardt acquires Protinex, Farex brands from Netherland Co
6. Indoco Remedies Acquires La Nova Chem
7. Ranbaxy Acquires Glaxosmithklines Generic Unit in Spain
8. AIIMS Acquires Four-Armed Robot to Assist in Surgeries
9. Apollos Global Arm Acquires US-based Firm
10. ‘Obesity’ Acquires Permanent Resident Status in the US
11. Indias Wockhardt Acquires Irish Firm
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... San Diego, CA (PRWEB) September 02, 2014 ... guide titled, “Is Group Therapy Right for Me?” The ... joining group therapy or counseling, in addition to common ... in group therapy improve not only from the interventions ... the group and receiving feedback from group members,” says ...
(Date:9/2/2014)... 2014 Friendship Village of Schaumburg ... “This creates a contemporary marketing presence and visually ... parent organization, Friendship Senior Options,” said Stephen A. ... “By changing the logo, we are making sure ... seniors and their families.” , Friendship Village is ...
(Date:9/2/2014)... Complications are rare among breast cancer patients who ... However, the researchers did find that a ... risk for certain complications than a single mastectomy. ... cancer patients who had a single (64 percent) ... were followed for 30 days after surgery. ...
(Date:9/2/2014)... WASHINGTON Patients who return to the emergency department within ... are anxious about their symptoms and have lost trust in ... results of a study published online today in Annals ... Department: The Patient Perspective" ). , "When asked ... reported feeling that their symptoms were too severe to wait ...
(Date:9/2/2014)... -- Two new studies further confirm the health benefits ... breast-fed have a lower risk of ear, throat and ... finds a similar trend when it comes to allergies. ... in the immediate newborn period," said Dr. Jennifer Wu, ... City. She was not involved in the new studies. ...
Breaking Medicine News(10 mins):Health News:Friendship Village of Schaumburg In Illinois Announces New Logo 2Health News:Complication Rates Low With Mastectomy, Breast Reconstruction: Study 2Health News:Discharged patients return to the ER because 'better safe than sorry' 2Health News:More Evidence Breast-Feeding Lowers Child's Risk of Infections, Allergies 2
... BALTIMORE, June 16 Lupin Pharmaceuticals, Inc. (LPI),announced ... the Company,s,Abbreviated New Drug Application (ANDA) for Escitalopram ... U.S. Food and Drug Administration (USFDA)., Lupin,s ... Laboratories, Lexapro(R) tablets, indicated for the treatment of,major ...
... Researchers at Ben-Gurion University of the Negev (BGU) in ... tested at a Washington, D.C. hospital, that enables doctors ... instead of touching a screen, keyboard or mouse which ... just released article. , The June article," A Gesture-based ...
... to injury-related deaths, the gap between black and white ... researchers at the Johns Hopkins Bloomberg School of Public ... injury-related deaths among blacks ages 15 to 24 decreased, ... published in the June, 2008, edition of Injury ...
... and PLM Based on Dassault Systemes, Newly,Introduced V6 Platform and ... ... ST. PAUL, Minnesota, June 16 Intercim LLC, a global,leader ... highly regulated industries and Dassault,Systemes (DS) (Nasdaq: DASTY; Euronext Paris: ...
... COLUMBIA, S.C., June 16 BlueCross BlueShield,of South ... of,the company,s health insurance plans that also adds ... options., "With increasing health care costs forcing ... dropping their insurance or not,picking it up to ...
... Coffee,s aroma kick-starts genes in the brain, Journal of ... a wake-up call to the brain? Or just smell its ... some of the first evidence that simply inhaling coffee aroma ... with laboratory rats, they found that coffee aroma orchestrates the ...
Cached Medicine News:Health News:Lupin Receives USFDA Approval for Escitalopram Oxalate Tablets 2Health News:Gesture interface device developed by Ben-Gurion University of the Negev 2Health News:Racial disparities reduced in injury related mortality 2Health News:Intercim and Dassault Systemes Sign Memorandum of Understanding 2Health News:Intercim and Dassault Systemes Sign Memorandum of Understanding 3Health News:S.C. BlueCross Launches Less-Costly Plans Geared to Groups Seeking More Options 2Health News:American Chemical Society's Weekly PressPac: June 11, 2008 2Health News:American Chemical Society's Weekly PressPac: June 11, 2008 3Health News:American Chemical Society's Weekly PressPac: June 11, 2008 4Health News:American Chemical Society's Weekly PressPac: June 11, 2008 5Health News:American Chemical Society's Weekly PressPac: June 11, 2008 6Health News:American Chemical Society's Weekly PressPac: June 11, 2008 7Health News:American Chemical Society's Weekly PressPac: June 11, 2008 8
(Date:9/2/2014)... Sept. 2, 2014 Reportlinker.com announces that ... its catalogue: Acute Heart Failure Global ... http://www.reportlinker.com/p0689743/Acute-Heart-Failure-Global-Clinical-Trials-Review-H2-2014.html Acute Heart Failure ... Summary GlobalData,s clinical trial report, "Acute Heart ... data on the Acute Heart Failure clinical trial ...
(Date:9/2/2014)... ALBANY, New York , September 2, 2014 ... market report published by Transparency Market Research "Latin ... and Monitoring Devices, Therapeutic Home Healthcare Devices, Mobility ... Telehealth and Telemedicine, Respiratory Therapy, Infusion Therapy and ... Share, Growth, Trends and Forecast, 2014 - 2020" ...
(Date:9/2/2014)... España, September 2, 2014 ... fibrilación atrial muestran agentes antitrombóticos no utilizados óptimamente ... -- Las presentaciones de GARFIELD-AF en el ... tratamiento y los resultados de pacientes en riesgo ... --    Los datos de casi ...
Breaking Medicine Technology:Acute Heart Failure Global Clinical Trials Review, H2, 2014 2Acute Heart Failure Global Clinical Trials Review, H2, 2014 3Acute Heart Failure Global Clinical Trials Review, H2, 2014 4Acute Heart Failure Global Clinical Trials Review, H2, 2014 5Acute Heart Failure Global Clinical Trials Review, H2, 2014 6Acute Heart Failure Global Clinical Trials Review, H2, 2014 7Acute Heart Failure Global Clinical Trials Review, H2, 2014 8Home Healthcare Market in Latin America Expected to Reach USD 17.5 Billion in 2020: Transparency Market Research 2Home Healthcare Market in Latin America Expected to Reach USD 17.5 Billion in 2020: Transparency Market Research 3Home Healthcare Market in Latin America Expected to Reach USD 17.5 Billion in 2020: Transparency Market Research 4Home Healthcare Market in Latin America Expected to Reach USD 17.5 Billion in 2020: Transparency Market Research 5Home Healthcare Market in Latin America Expected to Reach USD 17.5 Billion in 2020: Transparency Market Research 6Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 2Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 3Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 4Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 5Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 6Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 7Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 8Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 9Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 10Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 11
... PediaVision today announced that Loma Linda University,s Vision ... of California to receive the revolutionary new vision ... of Ophthalmology is offering free vision screenings to ... of First 5 Riverside , which invests ...
... DURHAM, N.C., Sept. 29, 2011 CoLucid Pharmaceuticals, Inc., ... Chief Executive Officer, Thomas P. Mathers, will be making ... Conference at 9:35 – 10:00 a.m. on Tuesday, October ... Hotel in Tokyo, Japan. The partnering meeting is expected ...
Cached Medicine Technology:Loma Linda University Expands Vision Screening Program With Revolutionary New Screening Device, Spot 2Loma Linda University Expands Vision Screening Program With Revolutionary New Screening Device, Spot 3Loma Linda University Expands Vision Screening Program With Revolutionary New Screening Device, Spot 4CoLucid Pharmaceuticals to Present at Sofinnova Japan Biopharma Partnering Conference on Tuesday, October 4th in Tokyo, Japan 2
The proximally modular S-ROM Total Hip System provides custom capability at non-custom prices and is competitive with conventional porous coated systems....
The proximally modular S-ROM Total Hip System provides custom capability at non-custom prices and is competitive with conventional porous coated systems....
Exactech's AcuMatch C-Series (Cemented Femoral Stem) is designed to provide solutions to the problems which compromise both the short and long term successful outcome of cemented hip arthroplasty....
Exactech's AcuMatch C-Series (Cemented Femoral Stem) is designed to provide solutions to the problems which compromise both the short and long term successful outcome of cemented hip arthroplasty....
Medicine Products: